Burns, Timothy F.

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 1,733

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 527

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 167

Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer

Chen, G., Gao, C., Gao, X., Zhang, D. H., Kuan, S.-F., Burns, T. F., & Hu, J. (2018) · Molecular Cancer Therapeutics

Colorectal Cancer Treatments and StudiesWnt/β-catenin signaling in development and cancer

Cited by 104

Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.

Heist, R. S., Koyama, T., Murciano-Goroff, Y. R., Hollebecque, A., Cassier, P. A., Han, J.-Y., Tosi, D., Sacher, A. G., Burns, T. F., Spira, A. I., et al. (2024) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 48

First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety

Strickler, J. H., Satake, H., Hollebecque, A., Sunakawa, Y., Tomasini, P., Bajor, D. L., Schuler, M. H., Yaeger, R., George, T. J., Garrido-Laguna, I., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 45

Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors

Ramalingam, S., Fakih, M., Strickler, J., Govindan, R., Li, B. T., Goldberg, S., Gandara, D., Burns, T., Barve, M., Shu, C., et al. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 40

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Murciano-Goroff, Y. R., Heist, R. S., Kuboki, Y., Koyama, T., Ammakkanavar, N. R., Hollebecque, A., Patnaik, A., Shimizu, T., Spira, A. I., Nagasaka, M., et al. (2023) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 40

Abstract P05-02: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)

Gandara, D., Marrone, K., Govindan, R., Skoulidis, F., Durm, G., Clarke, J., Frank, R., Krauss, J., Snyder, W., Dai, T., et al. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 24

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).

Gadgeel, S. M., Miao, J., Riess, J. W., Mack, P. C., Gerstner, G. J., Burns, T. F., Taj, A., Akerley, W. L., Dragnev, K. H., Moon, J., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 15

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 13

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Reuss, J. E., Gandhi, S. G., Spigel, D. R., Janne, P. A., Paz-Ares, L. G., Gadgeel, S. M., Patel, J. D., Passiglia, F., Spira, A. I., Edelman, M. J., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 7